Background: Cidofovir (CDV) is an acyclic nucleoside phosphonate that exhibits a potent antiviral activity against several DNA viruses. In previous studies, CDV has been shown to significantly reduce the clinical severity and the viral shedding in primary caprine herpesvirus type-1 (CpHV-1) infection in goats. CpHV-1 is an a-herpesvirus showing many biological similarities with human herpesvirus type-2 (HHV-2); therefore, studies conducted on the CpHV-1 goat model could provide useful information on the pathogenesis, therapy and prevention of HHV-2 infection in humans. Methods: CDV was administered to goats infected by vaginal route with CpHV-1. Real-time PCR was carried out on sacral ganglia from CpHV-1-infected goats to detect and quantify latent CpHV-1 DNA. Results: Viral DNA was variably found in all five pairs of sacral ganglia, with a more frequent involvement of the third and fourth pair. In CDV-treated goats, the amount of CpHV-1 DNA did not appear to be related either to the severity of the clinical signs or the titre of the virus shed during primary CpHV-1 infection. Conclusions: CDV failed to prevent CpHV-1 latency. Thus, vaginal CDV administration during primary herpesvirus infection, although providing immediate clinical benefits to the host might not influence the establishment of latency and, consequently, the rate of recurrent infections.
Caprine herpesvirus type-1 (CpHV-1) is a typical a-herpesvirus affecting goats, which is able to generate a systemic, often lethal, infection in 1-2-weekold kids and, commonly, subclinical respiratory and/ or genital infections in adult goats [1] . Clinical signs, when present, are restricted to the genital mucosa, and characterized by painful erythematous-oedematous lesions evolving into vesicles and ulcers that heal in approximately 2 weeks.
Goats might be infected by the nasal and/or the genital route. In the former case, virus replicates in the nasal mucosa and might then spread throughout the body and reach the genital tract inducing typical lesions with viral shedding [2] . In the latter instance, the infection is restricted to the genital mucosa with the occurrence of typical lesions and subsequent latency in the sacral ganglia [3, 4] . In a previous study, a qualitative PCR was able to reveal the presence of CpHV-1 DNA in the third and fourth pair of sacral ganglia and/or in the trigeminal ganglia of CpHV-1-infected goats [3] [4] [5] . The different sites of latency were found to depend on the route of viral entry and internal spreading. Previous studies have shown that CpHV-1 infection in goats closely mimics human herpesvirus type-2 (HHV-2) infection both in terms of genital lesions and humoral immune responses [2] [3] [4] [5] [6] [7] . Therefore, the CpHV-1 goat model might represent a valid animal model to study the efficacy of antiviral drugs and to test novel vaccines against HHV-2 infection. Among the antiherpetic drugs, cidofovir (CDV) is an acyclic nucleoside phosphonate with potent broad-spectrum anti-DNAvirus activity [8] [9] [10] . In previous studies the efficacy of vaginally administered CDV was evaluated in goats infected with CpHV-1 that had been treated using several therapeutic protocols [11] [12] [13] . High efficacy of CDV for reducing clinical signs and the titres of viral shedding in infected goats was observed. Until now, however, the latency of CpHV-1 in CDV treated goats has not been investigated.
In the present study, the distribution and quantification of CpHV-1 DNA in the sacral ganglia of goats infected with CpHV-1 and treated with CDV were evaluated by real-time PCR. 
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Methods
Animals and historical background of the samples
We examined sacral ganglia from 11 goats used in several experiments on the efficacy of CDV (1% cream) administered intravaginally against CpHV-1 infection [11] [12] [13] . All experiments were approved by the Italian Ministry of Health and carried out following the national guide for the care and use of experimental animals. The goats were euthanized approximately 5 months after the end of the respective experiments using 15 ml of enbutramide/mebezonio ioduro/tetracaina (Tanax ® ; Intervet Italia Srl, Milan, Italy) intravenously for each animal. The 11 goats, representative of different experimental groups, are reported in Table 1 .
Animals were divided into five groups (A, B, C, D and E) on the basis of their clinical and virological responses to CpHV-1 infection and CDV treatment. Group A included three goats that reacted successfully to the CDV treatment, showing no major clinical signs, with the exception of slight vaginal hyperaemia and a low titre of viral shedding limited to a few days. Group B included two goats that reacted partially to CDV treatment and had few clinical signs, such as a moderate hyperaemia and oedema, and recovered after a short period of time with moderate viral shedding in terms of titre and duration (days) of excretion. Group C included two goats that responded poorly to the drug, and developed severe genital lesions and viral shedding that were similar to those observed in the untreated infected goats [11] [12] [13] . Group D included two intravaginally infected goats that had not been treated with CDV (positive controls). Group E included two seronegative and uninfected goats, used as negative controls. For each animal, five pairs (left and right) of sacral ganglia were excised and subjected to real-time PCR for the detection and quantification of CpHV-1 DNA.
DNA preparation
Total DNA purification from ganglia (25 mg) was achieved by using the DNeasy Tissue Kit (Qiagen SpA, Milan, Italy), followed by final elution of DNA with 200 µl of elution buffer and storage at -70°C until use.
Real-time PCR assays
Primers and probe (Table 2 ) targeting a conserved region of the gC gene of the strain BA.1 of CpHV-1 (GenBank accession number AY821804) were designed using Beacon Designer software (Bio-Rad Laboratories Srl, Segrate, Italy) and purchased from MWG Biotech AG (Ebersberg, Germany). The TaqMan ® probe was labelled with the fluorescent reporter dye 6-carboxyfluoroscein at the 5′-end and with the quencher dye 6-carboxytetramethylrhodamine (Blackhole Quencher 1; MWG Biotech AG) at the 3′-end. The DNA extracts were tested by a CpHV-1 realtime PCR assay, following the method developed by Decaro et al. [14] and modified by Elia et al. [15] . Briefly, real-time PCR was carried out in a 25 µl reaction volume containing 12.5 µl of IQ™ Supermix (BioRad Laboratories Srl), 600 nM of primers CpHV-For and CpHV-Rev, 200 nM of probe CpHV-Pb and 10 µl of DNA. Serial 10-fold dilutions (from 10 9 to 10 2 DNA copies/10 µl of standard DNA) of a plasmid PGEM ® -3Z (Promega, Madison, WI, USA) containing the nearly full-length gC gene of CpHV-1 were used to generate a standard curve. Duplicates of the CpHV-1 standard dilutions and DNA templates were simultaneously subjected to real-time analysis. An exogenous internal control, consisting of 10,000 copies of canine parvovirus type-2 DNA [16] per ml of lysis buffer, was added to each sample prior to DNA preparation to control for PCR inhibition. Real-time PCR was carried out in an I-Cycler iQTM Real Time Detection System (Bio-Rad Laboratories Srl). The thermal cycle protocol involved activation of Taq DNA polymerase at 95°C for 10 min and 45 cycles, denaturation at 95°C for 1 min, then primer annealing and extension at 70°C for 1 min.
Results
Results are reported in Table 3 . As expected, ganglia of the seronegative goats (E1 and E2) were negative for viral DNA. The positive control goat, D1, had CpHV-1 DNA in 6/10 ganglia with viral DNA titres that ranged from 8. 
Discussion
Data on CpHV-1 latency in the sacral ganglia are very limited. In a previous paper, which employed a qualitative PCR assay, the third and fourth pair of sacral ganglia were found to be sites of latency for CpHV-1 in naturally infected goats [5] . By using real-time PCR, we have extended our knowledge of CpHV-1 latency. We detected CpHV-1 DNA in the first, second and fifth pair of ganglia, as well as in the third and fourth pairs, and determined the exact level of CpHV-1 DNA. Regarding the distribution of the CpHV-1 in the ganglia, a certain degree of variability was observed among goats of the different groups, as well as among goats of the same group. An important finding concerns the amount of CpHV-1 DNA in the ganglia. In this study, the amount Table 3 . Number of CpHV-1 DNA copies/25 mg of tissue detected in sacral ganglia by real-time PCR a Each group was infected intravaginally with 3 ml of caprine herpesvirus type-1 (CpHV-1) suspension (titre 10 6.5 median tissue culture infective dose/50 µl) and treated with cidofovir (CDV; group A, B and C). Goats in groups D were CpHV-1-infected and untreated (positive controls) and goats in group E were CpHV-1-uninfected (negative controls). of CpHV-1 DNA detected in individual ganglia ranged from 1.3×10 3 to 2.6×10 6 copies/25 mg of tissue; also, the amount of CpHV-1 did not appear related to the severity of clinical signs or to the amounts of virus shed during the primary infection. Most importantly, the results show that CDV was not able to block CpHV-1 latency in the sacral ganglia of vaginally infected goats. The failure to prevent latency was especially evident in the group A goats, although CDV prevented clinical signs and significantly decreased viral replication and shedding [11] [12] [13] .
Because the number of copies of HHV-2 DNA has also been reported to correlate with the rate of recurrent genital herpes outbreaks in humans [17, 18] , our findings suggest that CDV treatment would not be expected to influence the rate of recurrent human infections.
The results presented here might have implications for the follow-up of HHV-2-infected individuals and could provide useful information regarding the proper management of antiviral-treated clinical cases. CDV treatment would be expected to reduce the clinical and virological outcomes of CpHV-1 infection, that is, it might provide benefit to patients and reduce viral shedding. However, from an epidemiological perspective, latency and recurrence of CpHV-1 was not influenced by CDV antiviral treatment and, therefore, it would not be expected to contribute to the control of CpHV-1 infection in herds.
